, APAC
Photo from Envato

Sepsis drug development remains challenged amidst high trial failures

Currently, there are 14 drugs in late-stage development across eight major markets.

Sepsis, a condition caused by an abnormal immune response to infection, leads to millions of deaths globally each year. However, there is currently no drug specifically targetting the underlying mechanisms that cause the disease.

A GlobalData report revealed that key opinion leaders (KOLs) have cited the high failure rate of sepsis drug trials as a notable concern. Phase III trial failures for AM Pharma’s ReCAP and Asahi Kasei’s thrombomodulin alfa have contributed to this scepticism.

They also attributed these failures to the use of inappropriate trial endpoints and the recruitment of heterogeneous study groups.

Meanwhile, GlobalData infectious disease analyst Anaelle Tannen said that there was a significant lack of funding in this area, with only symptomatic treatments available for the condition.

“Enhancing awareness of sepsis is incredibly important, especially since the outcome of this disease is highly dependent on timely diagnosis and rapid initiation of therapeutics,” Tannen said.

The analyst suggested the increased use of artificial intelligence could help improve clinical trials by identifying homogenous patient populations based on specific biomarkers and matching these subgroups to specific drugs under investigation.

“This could increase the likelihood of approval of certain drugs for the treatment of sepsis,” Tannen added.

Currently, there are 14 drugs in late-stage development across eight major global markets (US, France, Germany, Italy, Spain, UK, Japan, and China).

 

Follow the links for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Exclusives

Saudi’s KFSHRC banks on innovation to transform healthcare
The hospital is accelerating adoption of emerging technologies to position itself as a global leader in medicine
Angkor Hospital eyes trauma centre for children
The facility will have an ICU, emergency room, operating theatre and a surgical ward.